Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Assess the Safety and Immunogenicity of DENVax Vaccine in Healthy Adults

NCT01224639 is registered in ClinicalTrials.gov with Inviragen Inc. as lead sponsor.

NCT NCT01224639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01224639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Assess the Safety and Immunogenicity of DENVax Vaccine in Healthy Adults
Lead sponsor
Inviragen Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 11, 2010
Completion date
November 9, 2011
Enrollment
96 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dengue fever